Related Experiment Video
Updated: May 24, 2026
10:17
An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
Published on: April 26, 2019
[Pediatric steatohepatitis: is it only obesity?]
C Amoruso1, M Farallo, C Frattini
1U.O. Pediatria 2-Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano.
Summary
Nonalcoholic steatohepatitis (NASH) in obese children can stem from Wilson's disease. This rare genetic disorder should be considered in diagnosing NASH to ensure accurate treatment for pediatric patients.
Area of Science:
- Hepatology
- Pediatric Gastroenterology
- Metabolic Disorders
Background:
- Nonalcoholic steatohepatitis (NASH) is increasingly diagnosed in obese children.
- Obesity is a primary risk factor for NASH, but other underlying causes exist.
- Wilson's disease is a rare genetic disorder affecting copper metabolism.
Observation:
- A case study of an 11-year-old obese child presenting with NASH is detailed.
- The child was diagnosed with both NASH and Wilson's disease.
- This co-occurrence highlights the importance of considering diverse etiologies for pediatric NASH.
Findings:
- Wilson's disease can manifest as nonalcoholic steatohepatitis (NASH) in pediatric cases.
- The study underscores that NASH in obese children is not solely attributable to obesity.
- Diagnostic exclusion of Wilson's disease is critical in obese children with NASH.
Implications:
- Clinicians should consider Wilson's disease in the differential diagnosis of NASH in obese children.
- Early identification and management of Wilson's disease can prevent severe liver damage.
- This case broadens the understanding of NASH etiology in pediatric populations.
Related Concept Videos
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:24Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:21Chronic Pancreatitis II: Pathophysiology
Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...